文献速递泌尿生殖与妇科肿瘤放疗

前列腺癌根治性及术后图像引导放疗期间患者报告的生活质量

Patient-reported quality of life during definitive and postprostatectomy image-guided radiation therapy for prostate cancer.
PubMed 文献 · Pract Radiat Oncol · 2016-08-12

研究前瞻性收集111例接受图像引导放疗的前列腺癌患者的生活质量数据,其中根治性放疗73例、前列腺切除术后放疗38例,采用经验证的前列腺癌症状指数评估泌尿和肠道症状。结果显示放疗期间泌尿和肠道症状有轻度增加,但多数在治疗结束后首次随访时接近基线水平,且长期新发症状不常见。

要点

  • 根治性放疗患者放疗结束时尿流和尿频的临床显著症状比例较基线增加。
  • 术后放疗患者尿频和夜尿的临床显著症状比例也较基线增加。
  • 放疗期间出现的泌尿或肠道症状多数在2年及以上时未持续存在。

核心结论

  • 根治性和术后图像引导放疗期间泌尿和肠道症状有轻度增加。
  • 这些数据有助于医患了解症状轨迹并合理预期治疗毒性。

研究设计与样本

  • 前瞻性收集111例前列腺癌患者的生活质量数据,使用经验证的前列腺癌症状指数评估5项泌尿梗阻/刺激症状和6项肠道症状。
  • 根治性放疗73例,前列腺切除术后放疗38例,分别分析多个时间点的症状频率和严重程度。

主要发现

  • 根治性放疗患者放疗结束时尿流临床显著症状比例为33% vs 基线19%,尿频为39% vs 18%。
  • 术后放疗患者尿频临床显著症状比例为29% vs 基线3%,夜尿为50% vs 21%。
  • 根治性放疗患者放疗结束时腹泻临床显著症状比例为9% vs 基线4%,尿急为12% vs 6%。
  • 肠道和泌尿症状在治疗结束后首次随访时接近基线水平。
  • 放疗期间有临床显著泌尿或肠道症状的大多数患者在2年及以上时没有这些症状,长期新发症状不常见。

临床怎么用

  • 可利用这些症状轨迹数据向患者说明放疗期间泌尿和肠道症状的预期变化。
  • 帮助医患对治疗毒性建立合理预期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The importance of patient-reported outcomes is well-recognized. Long-term patient-reported symptoms have been described for individuals who completed radiation therapy (RT) for prostate cancer. However, the trajectory of symptom development during the course of treatment has not been well-described in patients receiving modern, image-guided RT. METHODS AND MATERIALS: Quality-of-life data were prospectively collected for 111 prostate cancer patients undergoing RT using the validated Prostate Cancer Symptom Indices, which assessed 5 urinary obstructive/irritative and 6 bowel symptoms. Patients who received definitive RT (N = 73) and postprostatectomy RT (N = 38) were analyzed separately. The frequency and severity of symptoms over multiple time points are reported. RESULTS: An increasing number of patients had clinically meaningful urinary and bowel symptoms over the course of RT. A greater proportion of patients undergoing definitive RT reported clinically meaningful urinary symptoms at the end of RT compared with baseline in terms of flow (33% vs 19%) and frequency (39% vs 18%). Individuals receiving postprostatectomy radiation also reported an increase in symptoms including frequency (29% vs 3%) and nocturia (50% vs 21%). Clinically meaningful bowel symptoms were less commonly reported. Patients receiving definitive RT reported an increase in diarrhea (9% vs 4%) and urgency (12% vs 6%) at the completion of RT compared with baseline. Both bowel and urinary symptoms approached their baseline levels by the time of first follow-up after treatment completion. The majority of patients who had clinically meaningful urinary or bowel symptoms during RT did not have them at 2 years or beyond, and development of new symptoms in the long term was uncommon. CONCLUSIONS: There is a modest increase in urinary and bowel symptoms over the course of treatment for individuals receiving definitive and postprostatectomy image-guided RT. These data can help inform both providers and patients regarding the trajectory of symptoms and allow for reasonable expectations regarding toxicity under treatment.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Diao K, Lobos EA, Yirmibesoglu E, et al. Patient-reported quality of life during definitive and postprostatectomy image-guided radiation therapy for prostate cancer. Pract Radiat Oncol. 2016. PMID: 28274402. doi:10.1016/j.prro.2016.08.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。